VRDN News and Press, Viridian Therapeutics Inc Com

2024-07-16 11:10:14 ET More on Biogen, Pharvaris, etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Biogen Stock: Cheapish, But With Few Growth Prospects Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) ...

2024-07-15 09:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-08 10:38:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks, typically valued between $300 million and $2 billion, often promise notable growth potential and superior long-term returns. Now, with interest rate cuts on the horizon, inves...

2024-07-05 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-12 10:29:57 ET Summary Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients a...

2024-06-11 15:00:09 ET Gregory Renza from RBC Capital issued a price target of $35.00 for VRDN on 2024-06-11 12:47:00. The adjusted price target was set to $35.00. At the time of the announcement, VRDN was trading at $12.9625. The overall price target consensus is at $35...

2024-06-11 14:30:05 ET RBC Capital analyst issues OUTPERFORM recommendation for VRDN on June 11, 2024 12:47PM ET. The previous analyst recommendation was Outperform. VRDN was trading at $12.9625 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2024-06-11 09:14:04 ET More on Viridian Therapeutics Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript Viridian Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Viridian Therapeutics Hi...

- On track to initiate two phase 3 clinical trials of VRDN-003 in August 2024 - - REVEAL-1 and REVEAL-2, will evaluate two active dosing regimens of subcutaneously (SC) administered VRDN-003 in active and chronic thyroid eye disease (TED), with topline readout anticipated in the first hal...

2024-06-10 21:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for VRDN on June 10, 2024 07:02PM ET. VRDN was trading at $12.22 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 7 - Buy, 1 -...